- Home
- SHOT vs FGEN Comparison
SHOT vs FGEN Comparison
Compare SHOT & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- FGEN
- Stock Information
- Founded
- SHOT 2018
- FGEN 1993
- Country
- SHOT United States
- FGEN United States
- Employees
- SHOT N/A
- FGEN N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- SHOT Health Care
- FGEN Health Care
- Exchange
- SHOT Nasdaq
- FGEN Nasdaq
- Market Cap
- SHOT 33.1M
- FGEN 33.5M
- IPO Year
- SHOT 2020
- FGEN 2014
- Fundamental
- Price
- SHOT $0.36
- FGEN $0.32
- Analyst Decision
- SHOT
- FGEN Strong Buy
- Analyst Count
- SHOT 0
- FGEN 1
- Target Price
- SHOT N/A
- FGEN $10.00
- AVG Volume (30 Days)
- SHOT 635.3K
- FGEN 1.6M
- Earning Date
- SHOT 05-14-2025
- FGEN 03-17-2025
- Dividend Yield
- SHOT N/A
- FGEN N/A
- EPS Growth
- SHOT N/A
- FGEN N/A
- EPS
- SHOT N/A
- FGEN N/A
- Revenue
- SHOT $701,967.00
- FGEN $29,621,000.00
- Revenue This Year
- SHOT N/A
- FGEN $472.13
- Revenue Next Year
- SHOT N/A
- FGEN $7.13
- P/E Ratio
- SHOT N/A
- FGEN N/A
- Revenue Growth
- SHOT 68.01
- FGEN N/A
- 52 Week Low
- SHOT $0.34
- FGEN $0.18
- 52 Week High
- SHOT $2.46
- FGEN $2.40
- Technical
- Relative Strength Index (RSI)
- SHOT 29.09
- FGEN 38.86
- Support Level
- SHOT $0.41
- FGEN $0.30
- Resistance Level
- SHOT $0.50
- FGEN $0.38
- Average True Range (ATR)
- SHOT 0.04
- FGEN 0.05
- MACD
- SHOT -0.01
- FGEN -0.00
- Stochastic Oscillator
- SHOT 11.93
- FGEN 16.30
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.